Working… Menu

Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02277197
Recruitment Status : Completed
First Posted : October 28, 2014
Last Update Posted : April 18, 2019
AVEO Pharmaceuticals, Inc.
Information provided by (Responsible Party):
James J Lee, University of Pittsburgh

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : June 2016
Actual Study Completion Date : February 2018